论文部分内容阅读
目的观察黄葵胶囊联合福辛普利治疗慢性肾脏病轻、中度蛋白尿(1.0～3.5 g/24 h)的疗效及依从性。方法采用多中心、自身对照试验,为期12周。54例患者应用黄葵胶囊联合福辛普利治疗蛋白尿,治疗过程中检测血常规、尿常规、24小时尿蛋白定量、肝功能、肾功能、血电解质,并记录血压及不良反应情况。结果患者24小时尿蛋白定量试验前为(2.38±1.03)g,4周降至(1.89±0.77)g,P<0.01;8周降至(1.34±0.34)g,P<0.01;12周降至(0.77±0.57)g,P<0.01。11例完全缓解(23.9%);部分缓解10例(21.7%);部分有效21例(45.7%),无效4例(8.7%),总有效率91.3%。46例患者完成试验过程8,例患者未完成试验,其中疗效欠佳而停药3例,失访3例,因不可耐受的咳嗽退出2例。依从性为85.2%。结论黄葵胶囊联合福辛普利可显著减少慢性肾脏病患者的蛋白尿。患者对治疗的依从性较好。
Objective To observe the efficacy and compliance of Huang Kui capsule combined with fosinopril in the treatment of mild and moderate proteinuria (1.0 ~ 3.5 g / 24 h) in patients with chronic kidney disease. Methods A multicenter, self-controlled trial of 12 weeks. 54 patients were treated with Huang Kui capsules combined with fosinopril for the treatment of proteinuria, blood routine examination during treatment, urine routine, 24-hour urine protein, liver function, renal function, blood electrolytes, and blood pressure and adverse reactions were recorded. Results The level of urinary protein in 24 hours before the test was (2.38 ± 1.03) g, decreased to (1.89 ± 0.77) g in 4 weeks, P <0.01; decreased to (1.34 ± 0.34) g in 8 weeks, P <0.01; (0.77 ± 0.57) g, P <0.01.11 complete remission (23.9%); partial remission in 10 cases (21.7%); partial effective in 21 cases (45.7%) and ineffective in 4 cases (8.7% 91.3%. Forty-six patients completed the trial. Eight patients did not complete the trial. Among them, three were discontinued with poor response, three were lost to follow-up, and two were withdrawn due to intolerable cough. Compliance was 85.2%. Conclusion Huang Kui capsules combined with fosinopril can significantly reduce proteinuria in patients with chronic kidney disease. Patient compliance with treatment is better.